Business Context and Reporting Period
Company: NovaBridge Biosciences
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: July 2026
Key Event: Adoption of the 2026 Omnibus Share Incentive Plan by the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity plan authorization.
Material Changes
The primary material change is the authorization of a new equity incentive structure:
- Plan Name: 2026 Omnibus Share Incentive Plan (2026 Plan).
- Initial Authorization: 11,960,000 ordinary shares.
- Annual Increase Mechanism: Beginning January 1, 2027, the share pool will increase annually by the lesser of (i) 3% of outstanding shares as of the preceding December 31 or (ii) a smaller number determined by the Board.
- Term: Effective July 13, 2026, for a duration of ten years.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on operational outlook, or specific risk factors. The document serves to incorporate the new plan details by reference into existing Registration Statements (Form F-3 and Form S-8).
Key Facts for Investor Verification
- Verify the exact number of outstanding shares as of December 31, 2026, to calculate the potential share pool increase for 2027.
- Review the full text of the 2026 Omnibus Share Incentive Plan (Exhibit 99.1) for vesting schedules, eligibility criteria, and exercise terms.
- Assess the potential dilution impact of the initial 11,960,000 shares against the current float.